...
首页> 外文期刊>Pharmacognosy magazine >Discovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening
【24h】

Discovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening

机译:基于结构的虚拟筛选发现新型人类表皮生长因子受体2抑制剂

获取原文
           

摘要

Background: Human epidermal growth factor receptor-2 (HER2) is a trans-membrane receptor like protein, and aberrant signaling of HER2 is implicated in many human cancers, such as ovarian cancer, gastric cancer, and prostate cancer, most notably breast cancer. Moreover, it has been in the spotlight in the recent years as a promising new target for therapy of breast cancer. Objective: Since virtual screening has become an integral part of the drug discovery process, it is of great significant to identify novel HER2 inhibitors by structure-based virtual screening. Materials and Methods: In this study, we carried out a series of elegant bioinformatics approaches, such as virtual screening and molecular dynamics (MD) simulations to identify HER2 inhibitors from Food and Drug Administration-approved small molecule drug as potential “new use” drugs. Results: Molecular docking identified top 10 potential drugs which showed spectrum affinity to HER2. Moreover, MD simulations suggested that ZINC08214629 (Nonoxynol-9) and ZINC03830276 (Benzonatate) might exert potential inhibitory effects against HER2-targeted anti-breast cancer therapeutics. Conclusion: Together, our findings may provide successful application of virtual screening studies in the lead discovery process, and suggest that our discovered small molecules could be effective HER2 inhibitor candidates for further study. SUMMARY A series of elegant bioinformatics approaches, including virtual screening and molecular dynamics (MD) simulations were took advantage to identify human epidermal growth factor receptor-2 (HER2) inhibitors. Molecular docking recognized top 10 candidate compounds, which showed spectrum affinity to HER2. Further, MD simulations suggested that ZINC08214629 (Nonoxynol-9) and ZINC03830276 (Benzonatate) in candidate compounds were identified as potential “new use” drugs against HER2-targeted anti-breast cancer therapeutics. Abbreviations used : HER2: Human epidermal growth factor receptor-2, FDA: Food and Drug Administration, PDB: Protein Database Bank, RMSDs: Root mean square deviations, SPC: Single point charge, PME: Particle mesh Ewald, NVT: Constant volume, NPT: Constant pressure, RMSF: Root-mean-square fluctuation.
机译:背景:人类表皮生长因子受体2(HER2)是一种跨膜受体样蛋白,HER2的异常信号传导与许多人类癌症有关,例如卵巢癌,胃癌和前列腺癌,尤其是乳腺癌。此外,近年来,它已成为乳腺癌治疗的有希望的新靶标。目的:由于虚拟筛选已成为药物发现过程不可或缺的一部分,因此通过基于结构的虚拟筛选来鉴定新型HER2抑制剂具有重要意义。材料和方法:在这项研究中,我们进行了一系列优雅的生物信息学方法,例如虚拟筛选和分子动力学(MD)模拟,以从食品和药物管理局批准的小分子药物中鉴定HER2抑制剂为潜在的“新用途”药物。结果:分子对接确定了对HER2具有光谱亲和力的十大潜在药物。此外,MD模拟表明ZINC08214629(Nonoxynol-9)和ZINC03830276(Benzonatate)可能对靶向HER2的抗乳腺癌治疗剂具有潜在的抑制作用。结论:总之,我们的发现可能为虚拟筛选研究在先导发现过程中提供成功的应用,并表明我们发现的小分子可能是有效的HER2抑制剂候选者,需要进一步研究。概述利用一系列精美的生物信息学方法(包括虚拟筛选和分子动力学(MD)模拟)来鉴定人表皮生长因子受体2(HER2)抑制剂。分子对接识别出排名前10位的候选化合物,这些化合物对HER2具有光谱亲和力。此外,MD模拟表明,候选化合物中的ZINC08214629(Nonoxynol-9)和ZINC03830276(Benzonatate)被确定为针对HER2靶向抗乳腺癌治疗剂的潜在“新用途”药物。使用的缩写:HER2:人类表皮生长因子受体2,FDA:食品与药品管理局,PDB:蛋白质数据库银行,RMSD:均方根偏差,SPC:单点电荷,PME:Eesh颗粒网格,NVT:恒定体积, NPT:恒定压力,RMSF:均方根波动。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号